Amber H Nuyts1, Peter Ponsaerts1, Viggo F I Van Tendeloo1, Wai-Ping Lee1, Barbara Stein1, Guy Nagels2, Marie B D'hooghe2, Barbara Willekens3, Patrick Cras3, Kristien Wouters4, Herman Goossens1, Zwi N Berneman1, Nathalie Cools5. 1. Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (Vaxinfectio), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium. 2. Department of Neurology, National Center for Multiple Sclerosis, Melsbroek, Belgium and Center for Neurosciences, Universitair Ziekenhuis Brussel en Vrije Universiteit Brussel, Belgium. 3. Laboratory of Neurology, Born Bunge Institute, Translational Neurosciences, Faculty and Health Sciences, University of Antwerp and Division of Neurology, Antwerp University Hospital, Edegem, Belgium. 4. Department of Scientific Coordination and Biostatistics, Antwerp University Hospital, Edegem, Belgium. 5. Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (Vaxinfectio), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium. Electronic address: nathalie.cools@uza.be.
Abstract
BACKGROUND AIMS: Dendritic cell (DC)-based immunotherapy has shown potential to counteract autoimmunity in multiple sclerosis (MS). METHODS: We compared the phenotype and T-cell stimulatory capacity of in vitro generated monocyte-derived DC from MS patients with those from healthy controls. RESULTS: Except for an increase in the number of C-C chemokine receptor 7-expressing DC from MS patients, no major differences were found between groups in the expression of maturation-associated membrane markers or in the in vitro capacity to stimulate autologous T cells. CONCLUSIONS: Our observations may pave the way for the development of patient-tailored DC-based vaccination strategies to treat MS.
BACKGROUND AIMS: Dendritic cell (DC)-based immunotherapy has shown potential to counteract autoimmunity in multiple sclerosis (MS). METHODS: We compared the phenotype and T-cell stimulatory capacity of in vitro generated monocyte-derived DC from MSpatients with those from healthy controls. RESULTS: Except for an increase in the number of C-C chemokine receptor 7-expressing DC from MSpatients, no major differences were found between groups in the expression of maturation-associated membrane markers or in the in vitro capacity to stimulate autologous T cells. CONCLUSIONS: Our observations may pave the way for the development of patient-tailored DC-based vaccination strategies to treat MS.
Authors: Wai-Ping Lee; Barbara Willekens; Patrick Cras; Herman Goossens; Eva Martínez-Cáceres; Zwi N Berneman; Nathalie Cools Journal: J Immunol Res Date: 2016-09-14 Impact factor: 4.818
Authors: Anja Ten Brinke; Marc Martinez-Llordella; Nathalie Cools; Catharien M U Hilkens; S Marieke van Ham; Birgit Sawitzki; Edward K Geissler; Giovanna Lombardi; Piotr Trzonkowski; Eva Martinez-Caceres Journal: Front Immunol Date: 2019-02-22 Impact factor: 7.561
Authors: Luke M Healy; Jeong Ho Jang; So-Yoon Won; Yun Hsuan Lin; Hanane Touil; Salman Aljarallah; Amit Bar-Or; Jack P Antel Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-10-16